Clinigen Group Plc completed the acquisition of Idis Group Holdings Limited from management, CBPE Fund VII LP, managed by CBPE Capital LLP, and other sellers.
The transaction is subject to the private placement becoming unconditional, admission of new shares issued on London Stock Exchange. The transaction is subject to complete on April 29, 2015. The acquisition is expected to be immediately earnings enhancing and significantly enhancing in the first full year of ownership and the level of enhancement is expected to improve further in 2017. James Black and Tom Ballard of Numis Securities Limited acted as broker for Clinigen Group. Michael Meade and Freddie Barnfield of Numis Securities Limited acted as financial advisor for Clinigen Group. James Steel and Alastair Rae of Peel Hunt LLP acted as joint broker for Clinigen. Adrian Duffield and Melanie Toyne-Sewell of Instinctif Partners acted as media relations advisors for Clinigen. Richard Moulton, Louise Finnie, Andy Lord, Danny Blum and Richard Sharman of Eversheds LLP acted as legal advisor for CBPE Capital LLP. Julian Hudson and Chris Whittaker of N M Rothschild & Sons Limited acted as financial advisors for CBPE Capital LLP. Graham Elsworth, David Billington and Costas Kazamias of BDO acted as due diligence advisor in the transaction. KPMG LLP (United Kingdom) acted as an accountant for vendor. PricewaterhouseCoopers International Limited acted as an accountant and Addleshaw Goddard Ltd. acted as legal advisor for Clinigen Group Plc. Smith Square Partners LLP acted as financial advisor to Clinigen Group Plc (AIM:CLIN).
Clinigen Group Plc (AIM:CLIN) completed the acquisition of Idis Group Holdings Limited from management, CBPE Fund VII LP, managed by CBPE Capital LLP, and other sellers on April 29, 2015.